Brokers Set Expectations for PRLD Q3 Earnings

Prelude Therapeutics Incorporated (NASDAQ:PRLD) – Research analysts at HC Wainwright issued their Q3 2025 earnings estimates for shares of Prelude Therapeutics in a research report issued on Tuesday, September 23rd. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($0.35) per share for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Prelude Therapeutics’ current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Prelude Therapeutics’ Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.51) EPS, Q1 2026 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.32) EPS and FY2026 earnings at ($1.24) EPS.

Prelude Therapeutics (NASDAQ:PRLD) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.04.

Separately, JMP Securities lowered their price objective on shares of Prelude Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Monday, August 18th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $4.00.

Prelude Therapeutics Price Performance

Shares of PRLD opened at $1.22 on Thursday. The company has a market cap of $69.05 million, a PE ratio of -0.74 and a beta of 1.25. The firm has a 50-day moving average of $1.02 and a 200-day moving average of $0.90. Prelude Therapeutics has a one year low of $0.61 and a one year high of $2.25.

Hedge Funds Weigh In On Prelude Therapeutics

Several hedge funds have recently bought and sold shares of PRLD. Millennium Management LLC lifted its position in shares of Prelude Therapeutics by 188.2% during the fourth quarter. Millennium Management LLC now owns 462,555 shares of the company’s stock valued at $590,000 after buying an additional 302,031 shares during the last quarter. Two Sigma Advisers LP increased its stake in shares of Prelude Therapeutics by 526.3% in the 4th quarter. Two Sigma Advisers LP now owns 300,000 shares of the company’s stock worth $382,000 after acquiring an additional 252,100 shares during the last quarter. Two Sigma Investments LP grew its position in Prelude Therapeutics by 307.2% in the 4th quarter. Two Sigma Investments LP now owns 231,839 shares of the company’s stock valued at $296,000 after acquiring an additional 174,906 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Prelude Therapeutics by 747.6% in the 4th quarter. Deutsche Bank AG now owns 123,899 shares of the company’s stock valued at $159,000 after buying an additional 109,281 shares during the period. Finally, Jane Street Group LLC purchased a new position in shares of Prelude Therapeutics in the 2nd quarter valued at about $74,000. Institutional investors own 79.72% of the company’s stock.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.